Monday, February 16, 2026 2/16/2026

CRISPR-induced cardiovascular progenitor cells to repair myocardial infarction

Award Number: R01HL157456
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

CRISPR-induced cardiovascular progenitor cells to repair myocardial infarction - Project Summary/Abstract Cardiovascular disease associated with myocardial infarction (MI) remains a major cause of death worldwide. Cell reprogramming into cardiovascular progenitor cells (CPCs), bypassing the process of pluripotency induction, has provided a promising approach for cardiac repair through simultaneous neovascularization and cardiomyogenesis. One significant gap in current research is an unclear understanding of the mechanisms of direct reprogramming. The activation of endogenous genetic loci (that are occluded by repressive chromatin marks) in starting cells has been considered an important criterion of high-quality fully reprogrammed cells. Therefore, we attempt to obtain a new source of CPCs through direct manipulation of endogenous genes. To this end, we propose a combined use of reprogramming technologies and CRISPR-based tools. CRISPR-induced gene activation is superior to conventional techniques employing cDNA overexpression due to its effectiveness, simplicity of design and avoidance of the need for additional transduction of transcription factor complexes. Our preliminary data demonstrates that CRISPR-induced cells possess the properties of CPCs including clonality, self- renewal, and cardiac tri-potentiality. Importantly, the CRISPR-induced CPCs (iCPCs) can blunt the worsening of heart function and reduce infarct size after transplantation in MI mice. These findings are the basis for a further systematic investigation of CRISPR-iCPCs in a preclinical setting. Accordingly, three Specific Aims are proposed to develop a technical platform to generate new CRISPR-iCPCs, study cell-reprogramming mechanisms, and evaluate the application of iCPCs for MI therapy. In Aim-1, a new non-viral CRISPR system will be developed for generation of iCPCs using a clinically acceptable gene vector system and the biological and functional features of new iCPCs will be characterized. In Aim-2, epigenetic factors mediating iCPC generation will be the focus of experiments. Long non-coding RNAs and targeted epigenetic mediators will be investigated to dissect the mechanisms of cellular reprogramming. In Aim-3, iCPCs will be implanted using cell patch techniques, and their cell fate decisions will be tracked in the infarcted heart. The extent and role of differentiated iCPCs will be determined by in vivo imaging and distinguished from other consequences using a cell ablation approach. In conclusion, this proposal will provide a new regeneration strategy for MI therapy through convergence of CRISPR technology and tissue engineering in CPC development.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $564,836 )
2024	2024	CINCINNATI UNIV OF	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	001	4	6/20/2024	NON-COMPETING CONTINUATION	$46,110
2024	2024	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	000	4	3/30/2024	NON-COMPETING CONTINUATION	$518,726
														Subtotal = $564,836

Issue Date FY: 2023 ( Subtotal = $577,574 )
2023	2023	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	000	3	3/6/2023	NON-COMPETING CONTINUATION	$577,574
														Subtotal = $577,574

Issue Date FY: 2022 ( Subtotal = $547,786 )
2022	2022	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	001	2	5/31/2022	NON-COMPETING CONTINUATION	$54,780
2022	2022	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	000	2	4/4/2022	NON-COMPETING CONTINUATION	$493,006
														Subtotal = $547,786

Issue Date FY: 2021 ( Subtotal = $692,459 )
2021	2021	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	001	1	7/2/2021	NEW	$69,244
2021	2021	UNIVERSITY OF CINCINNATI	2600 CLIFTON AVE	CINCINNATI	OH	45220	HAMILTON	USA	Cardiovascular Diseases Research	000	1	3/15/2021	NEW	$623,215
														Subtotal = $692,459

Grand Total All Awards = $2,382,655

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CRISPR-induced cardiovascular progenitor cells to repair myocardial infarction

Award Number: R01HL157456

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer